Clinical Trial Update: A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer [Phase 2]

View source ↗

Summary

This document reports a Phase 2 clinical study of 9MW2821 in combination with a PD-1 inhibitor for locally advanced or metastatic triple-negative breast cancer,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• 9MW2821
• PD-1 inhibitor

Snippet

Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd. | Conditions: Triple-Negative Breast Cancer | Phase 2 | Status: RECRUITING